Real-world investigation for camrelizumab combined with apatinib in patients with advanced hepatocellular carcinoma.

ABSTRACT: Apatinib, an oral tyrosine kinase inhibitor, combined with camrelizumab, a programmed cell death protein 1 inhibitor, has shown promising treatment efficacy for patients with advanced hepatocellular carcinoma (HCC). However, real-world evidence supporting this combination regimen is limited, and prognostic factors for these patients have not been thoroughly investigated. Therefore, the present real-world study aimed to assess the efficacy and safety of camrelizumab plus apatinib in patients with advanced HCC, and identify prognostic factors associated with response to treatment. A total of 39 patients with advanced HCC who received camrelizumab combined with apatinib were included in the present retrospective study. All patient data, such as treatment response, follow-up outcomes and incid

SUBMITTER: Yin L 

PROVIDER: S-EPMC12512521 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature